Section editor
	Elizabeth J. Davis, MD Vanderbilt University Nashville, TN ejdavis25

Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.

1 regimens on this page 1 variants on this page

All lines of therapy

Tazemetostat monotherapy

back to top

FDA-recommended dose

Study	Evidence
See note	Phase II (RT)

Note: this study has not yet been published, to our knowledge.

Continued indefinitely